Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Open original sourceLoading market dashboard
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Open original source